WDB COCO

Basic Information

Stock Code
7079
Industry
Services
Category Detail
Professional Services for Businesses
Prefecture
Tokyo
Establishment Year
August 1984
Listing Year
December 2019
Official Website
https://www.wdbcoco.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Human Adjust, Asia Q, Outlook, Elan, Solasto, Hyuga Pra, Mental Health Technologies, Emimen

Overview

WDB COCO is a leading Tokyo-based company founded in 1984, specializing primarily in support for pharmaceutical and medical device development, with strengths in safety information management services.

Current Situation

WDB COCO recorded sales of approximately 5.3 billion yen, operating profit of approximately 1.3 billion yen, and net profit of approximately 900 million yen for the fiscal year ending March 2025, maintaining solid performance. Its core business involves safety information management and related documentation support during clinical trials and post-marketing surveillance, covering a wide range of pharmaceutical development processes. The company also focuses on staffing and recruitment services, providing specialized services tailored to the pharmaceutical, medical, and biotech sectors. It has a wealth of contracts from major domestic pharmaceutical companies, differentiating itself from competitors. In 2024, it opened the Kobe Training Center to improve operational efficiency and talent development. The company emphasizes sustainability, thoroughly complying with laws and maintaining quality control. Looking ahead, it aims to expand development support services for medical DX and digitalization, strengthening its business foundation.

Trivia

Interesting Facts

  • Started in 1984 with pharmaceutical translation services.
  • Specializes in pharmaceutical safety management as a subsidiary of the WDB Group.
  • Established its own training center in Kobe.
  • One of Japan's leading companies capable of handling full ICSR processing outsourcing.
  • High expertise in documentation for pharmaceutical development support.
  • As of 2024, has 577 employees (including temporary staff).
  • Conducts business in both safety information management and staffing.
  • Head office located in Triton Square, Chuo-ku, Tokyo.
  • Internalized clinical research support business in 2024.
  • Audited by Deloitte Touche Tohmatsu.
  • Listed on the Tokyo Stock Exchange Growth Market.
  • Many shareholders are WDB Holdings-related entities.
  • Strength in multilingual translation of safety information.
  • Provides high-quality services to numerous pharmaceutical companies.
  • Aggressively investing in the Kansai region for business expansion.

Hidden Connections

  • As a 100% subsidiary of WDB Holdings, contributes to pharmaceutical development in an integrated group manner.
  • Vertical integration of services advanced through absorption and merger of clinical research subsidiary.
  • Kobe Training Center is an advanced education hub even in the industry.
  • High trust from pharmaceutical companies, with numerous long-term contracts.
  • Supports international expansion with specialized multilingual translation services for the pharmaceutical industry.
  • Immediate response to customer needs through flexible staffing services.
  • Enhanced fundraising capabilities through stock listing on the Tokyo Stock Exchange Growth Market.
  • Long-term positive relationship with audit firm Deloitte Touche Tohmatsu due to quality-focused stance.

Future Outlook

Growth Drivers

  • Globalization of pharmaceutical development and increasing sophistication of safety requirements
  • Growing demand for support services in digital health fields
  • Expansion and diversification of clinical research support needs
  • Increased demand for specialized services due to strengthened pharmaceutical regulations
  • Business efficiency and value enhancement through medical DX promotion
  • Growth in staffing and recruitment services
  • Expansion of outsourcing market accompanying acceleration of new drug development in the pharmaceutical industry
  • Enhancement of support framework through strengthening of regional bases
  • Brand value improvement through sustainability-focused operations
  • Overseas customer development through strengthened multilingual capabilities
  • Business innovation through utilization of IT tools and AI technologies
  • Strengthened collaboration with consulting business

Strategic Goals

  • Expansion of market share in domestic and international pharmaceutical safety-related markets
  • Doubling the business scale of clinical research support services
  • Achieving full digitalization of all sales processes through DX promotion
  • Realizing sustainable work style reforms and diversity respect
  • Strengthening quality management systems to meet international standards
  • Expansion of training and talent development programs
  • Maximizing operational efficiency across multiple bases
  • Stabilization and resilience of supply chain
  • Development and introduction of medical DX-related technologies
  • Continuously achieving customer satisfaction of 95% or higher

Business Segments

Safety Information Management Outsourcing Service

Overview
Comprehensive outsourcing of safety information management for pharmaceuticals and medical devices, accommodating diverse operational formats.
Competitiveness
High-quality service delivery backed by highly specialized personnel and extensive track record
Customers
  • Pharmaceutical manufacturers
  • Medical device manufacturers
  • Biotech ventures
  • CROs
  • Pharmaceutical development support companies
Products
  • ICSR processing
  • Safety evaluation report creation
  • Literature screening
  • Translation services
  • Dispatched safety management staff

Document Creation Support Service

Overview
Supports document creation for approval applications with high expertise.
Competitiveness
Rapid application response capabilities leveraging eCTD compilation experience
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Regulatory authorities
  • Approval application agents
  • Translation companies
Products
  • Approval application document creation
  • eCTD compilation
  • Translation and QC
  • Application document management

Post-Marketing Surveillance (PMS) Support

Overview
Provides one-stop support services for PMS-related surveys and data management.
Competitiveness
Flexible service system capable of handling facility-level support and large-scale projects
Customers
  • Medical institutions
  • Pharmaceutical companies
  • Survey organizations
  • Medical facility contractors
Products
  • Contract management
  • Survey explanations
  • Monitoring
  • Case registration
  • Statistical analysis

Clinical Research Support Service

Overview
Provides one-stop support services tailored for low-budget clinical research.
Competitiveness
Expertise and support capabilities specialized for unique needs in clinical research
Customers
  • University research institutions
  • Hospitals and clinics
  • Pharmaceutical companies
  • Researchers and academic societies
Products
  • Document creation
  • Monitoring
  • Data management
  • Report creation

Competitive Advantage

Strengths

  • High expertise specialized in pharmaceutical safety information management
  • Extensive track record in clinical trial-related document creation
  • Flexible operational format対応 and customization capabilities
  • Strong transaction base with major domestic pharmaceutical companies
  • Advanced translation and QC service technologies
  • Operational efficiency through multi-location operations
  • Thorough legal compliance and quality management systems
  • Securing of experienced specialized staff
  • Utilization of WDB Group resources
  • Enthusiasm for introducing latest technologies
  • Coverage of wide range of pharmaceutical and medical device fields
  • Solid financial foundation
  • High customer satisfaction
  • Advanced equipment in data centers
  • Sustainable business operations framework

Competitive Advantages

  • High brand recognition in the safety information management field within the industry
  • Total support covering all processes in pharmaceutical development
  • Specialized technical strength in eCTD creation
  • Provision of rapid and accurate translation and document QC services
  • Flexible talent supply through dispatched services
  • Stable operations via multiple data centers
  • Sharing of human and technical resources within the WDB Group
  • High transparency in legal compliance and quality assurance systems
  • Utilization of expert network in pharmaceutical safety domain
  • Reliability ensured by extensive track record
  • Multifaceted expansion of clinical research support services
  • Service design capabilities tailored to customer needs
  • Nationwide support through regional bases
  • Business efficiency improvement via introduction of latest IT tools
  • Optimal solution proposals through collaboration between sales and technology

Threats

  • Increased workload and burden due to stricter pharmaceutical development regulations
  • Diversification and advancement of competitors' services
  • Difficulty in securing staff due to talent shortage
  • Decline in competitiveness from delays in digitalization
  • High difficulty of overseas market entry
  • Risks from frequent legal and regulatory changes
  • Profit pressure from customers' cost reduction demands
  • Decline in competitiveness from delays in adopting new technologies or AI
  • Increased business risks due to uncertain external environment
  • Risk of operational halt from disasters
  • Threat of data security breaches
  • Price competition from intensifying inter-company rivalry

Innovations

2024: Opening of Kobe Training Center

Overview
Established a state-of-the-art training facility to enhance specialized staff skills.
Impact
Improved talent development efficiency and further enhancement of service quality

2023: Absorption and merger of clinical research subsidiary

Overview
Absorbed and merged WDB Clinical Research Co., Ltd. to strengthen clinical research support business.
Impact
Enhanced market competitiveness through expanded service range

2022: Transition to Tokyo Stock Exchange Growth Market

Overview
Responded to stock market reorganization to strengthen position in capital markets.
Impact
Improved fundraising capabilities and increased investor trust

2021: Relocation of Kansai office and Kobe Operation Center

Overview
Upgraded bases for improved convenience and operational efficiency.
Impact
Enhanced operational flexibility and customer response capabilities

2020: Introduction of web-based work management system

Overview
Introduced system development to improve efficiency in safety information management operations.
Impact
30% improvement in processing speed and reduction in human errors

Sustainability

  • Strengthening compliance through thorough legal adherence
  • Continuous improvement and transparency enhancement of quality management systems
  • Creating a comfortable work environment for employees and promoting health management
  • Business activities emphasizing harmony with local communities
  • Promotion of digitalization to reduce environmental impact
  • Promotion of diversity and inclusion
  • Implementation of sustainable talent development programs
  • Social contributions through safe and reliable pharmaceutical development support
  • Strengthening information security measures
  • Formulation of business continuity plans for disaster risks